Disc Medicine, INC 8-K filings

Disc Medicine reported Q2 2026 financial results, highlighting strong cash position and progress across its hematologic disease pipeline, with key data readouts expected in late 2026.

Disc Medicine has amended its loan agreement with Hercules Capital, extending drawdown periods for future advances and modifying cash covenant terms.

Disc Medicine, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of directors and ratification of its accounting firm.

Disc Medicine announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline and a strong cash position.

Disc Medicine, Inc. announced a 20% workforce reduction and a $2.0 million restructuring charge following an FDA Complete Response Letter for its drug bitopertin.

Disc Medicine announced its Q4 and full-year 2025 financial results, highlighted by pipeline progress and a strong cash position, despite a Complete Response Letter for bitopertin.

Disc Medicine received a Complete Response Letter from the FDA for its bitopertin New Drug Application, requiring additional clinical data from the ongoing APOLLO study.

Disc Medicine announced the FDA issued a Complete Response Letter for its New Drug Application for bitopertin as a treatment for erythropoietic protoporphyria, citing insufficient clinical endpoint correlation despite biomarker efficacy.

Disc Medicine announced preliminary unaudited cash of $791 million as of December 31, 2025, alongside significant pipeline progress and key milestones for 2026, including an anticipated FDA approval for bitopertin.

Disc Medicine provides positive updates on its clinical pipeline, including Bitopertin's NDA acceptance and promising Phase 2 data for DISC-0974 in anemia of myelofibrosis.

Disc Medicine reports Q3 2025 financial results, highlights bitopertin NDA submission with FDA priority voucher, and extends cash runway into 2029.

Disc Medicine, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering, raising approximately $210.9 million in net proceeds to extend its cash runway into 2029.

Disc Medicine provides a comprehensive update on its hematology portfolio, highlighting accelerated timelines for bitopertin approval, positive clinical data for DISC-0974 in myelofibrosis, and progress for DISC-3405, supported by a strong cash position of $615.9 million.

Disc Medicine, Inc. announced it received a Commissioners National Priority Voucher from the FDA for bitopertin, aimed at accelerating the review of its New Drug Application for erythropoietic protoporphyria.

Dr. Mona Ashiya resigns from Disc Medicine's Board of Directors, reducing its size to eight members.

Disc Medicine reports Q2 2025 financial results and provides key updates on its clinical pipeline, including progress towards an NDA submission for bitopertin and advancements in DISC-0974 and DISC-3405 programs.

Disc Medicine, Inc. announced the election of Nadim Ahmed as a new Class I director to its Board of Directors, effective July 14, 2025.

Disc Medicine, Inc. stockholders approved all four proposals at their 2025 Annual Meeting, including the election of three Class II directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as their independent auditor.

Disc Medicine reports a strong financial position with $695 million in cash and progress across its pipeline, including plans to submit an NDA for bitopertin in H2 2025.

Disc Medicine reports strong financial results for 2024 and provides updates on its clinical programs, including plans for an NDA submission for bitopertin in H2 2025.

Disc Medicine successfully priced an upsized public offering, raising $225.5 million through the sale of common stock and pre-funded warrants.

Disc Medicine has received positive feedback from the FDA regarding the design of its APOLLO post-marketing confirmatory trial for bitopertin in EPP and XLP, and plans to submit an NDA in the second half of 2025.

Disc Medicine announced its 2025 strategic priorities, highlighting advancements in its hematology pipeline and plans for potential accelerated approval of bitopertin.

Disc Medicine presented updated clinical data for bitopertin, DISC-0974, and DISC-3405 at the 66th American Society of Hematology Annual Meeting, highlighting progress and future plans for their hematology-focused pipeline.

Disc Medicine has established a new at-the-market equity offering program with Cantor Fitzgerald, allowing the company to sell up to $200 million of its common stock.

Disc Medicine reported positive progress with its pipeline, including a successful FDA meeting for bitopertin and promising data for DISC-0974, alongside a strong cash position boosted by a recent debt financing.

Disc Medicine has secured a $200 million non-dilutive term loan facility from Hercules Capital to support its clinical development programs.

Disc Medicine announced positive feedback from the FDA regarding their end-of-Phase 2 meeting for bitopertin in erythropoietic protoporphyria (EPP), including the potential for accelerated approval.

Disc Medicine reported positive results from a Phase 1b trial of DISC-0974, showing significant improvements in key markers for anemia in patients with non-dialysis-dependent chronic kidney disease.

Disc Medicine reported positive clinical data across its pipeline and strengthened its financial position with a $178 million capital raise.